Lipoproteína(a)
Grupo Argentino Estudio Lipoproteína (a)
.png)
Últimas Novedades
BMC Cardiovasc Disord. 2025 Dec 22;26(1):60. doi: 10.1186/s12872-025-05461-6.
Autores:
Ivette Cruz-Bautista 1 2 , Yuscely Flores-Jurado 3 , Antonio Barajas-Martínez 3 4 , Yulino Castillo-Núñez 5 , Daniel Elías-López 6 3 , María Alejandra Ramos-Guifarro 7 , Ramon Barrera-Cruz 8 , Lizbeth Ruilova-González 9 , Misael Aguilar-Panduro 3 , Liliana Muñoz-Hernández 3 10 , Roopa Mehta 6 3 , Raquel N Faradji 11 , Eduardo Márquez-Rodríguez 11 , Juan Carlos Garnica-Cuellar 11 , Samantha Gutiérrez-Morales 3 , José de Jesús Garduño-García 11 12 , José Alberto Ávila-Funes 13 , Arturo Guerra-López 14 , Alejo Diaz-Aragón 14 , Edith Ruiz-Gastelum 14 , Jorge Cossio-Aranda 15 , Raúl Velasco-Solorzano 16 , Pablo Corral 17 18 , Carlos O Mendívil 19 20 21 , Juan Patricio Nogueira 22 23 , Mario Morales-Esponda 6 , Carlos Alberto Aguilar-Salinas 3 4 ; Grupo Lípidos SMNE
Conclusión: Awareness and clinical use of Lp(a) testing among LATAM physicians remain limited and focused on high-risk scenarios. Improving test accessibility, providing clearer clinical guidelines, and reinforcing the evidence for Lp(a) as a therapeutic target may enhance its adoption and integration into cardiovascular risk assessment across the region.
Clin Res Cardiol. 2026 Feb;115(2):357-365. doi: 10.1007/s00392-025-02826-x. Epub 2025 Dec 16.
Autores:
Netanel Golan 1 , Ophir Freund 2 , Tamar Itach 1 , Yaron Arbel 3
Conclusión: In a large ambulatory and mostly healthy cohort, Lp(a) showed a strong predictive utility for cardiovascular events. These findings support the integration of Lp(a) into primary cardiovascular risk assessment and role in guiding emerging targeted therapies.
Clin Res Cardiol. 2026 Feb;115(2):322-334. doi: 10.1007/s00392-025-02751-z. Epub 2025 Aug 28.
Autores:
Oliver Weingärtner 1 2 , Simon Glück 3 4 , Karl Werdan 3 5 , Jessica Schorr 6 , Daniel Thieme 6 , Ana de la Llave 7 , Christian von Vultée 7 , Winfried Haerer 3 8
Conclusión: A large proportion of ASCVD patients in Germany are inadequately treated, with notable differences between GPs and OBCs. Additionally, gender and age-related disparities are evident. There is a clear need for these gaps to be addressed to improve cross-sectional patient care.
Phenomapping of subgroups in high-Lp(a) patients: a data-driven cluster analysis in RED-CARPET study
Clin Res Cardiol. 2026 Feb;115(2):255-265. doi: 10.1007/s00392-025-02669-6. Epub 2025 Jun 23.
Autores:
Shaozhao Zhang # 1 2 , Xiaoyu Lin # 3 , Rongjian Zhan # 4 , Huimin Zhou 1 2 , Yuhui Lai 1 2 , Mengting Huang 1 2 , Bingzhen Li 1 2 , Xinxue Liao 5 6 , Xiaodong Zhuang 7 8
Conclusión: Using a data-driven approach, high-Lp(a) patients can be stratified into four phenotypically distinct subgroups with different ASCVD risk.
Clin Res Cardiol. 2026 Feb;115(2):198-207. doi: 10.1007/s00392-024-02427-0. Epub 2024 Apr 15.
Autores:
Christoph Altmann 1 , Nelu-Adrian Burlacu 2 , Thomas Preuss 3 , Annett Hlousek 4 , Stephan Eddicks 2 ; MEDIAN Medical Board Cardiology
Conclusión: Lp(a) had been rarely assessed in acute management of aortic valve stenosis or premature myocardial infarction despite expanding scientific evidence and guideline recommendation. Given the above-average incidence of elevated Lp(a) levels, awareness for Lp(a) has to increase substantially to better identify and manage high-risk patients.
Conclusion: The following review aims to provide a comprehensive overview of the latest evidence on the factors driving residual CV risk and the therapeutic interventions available to treat atherogenic dyslipidaemia beyond LDL-C reduction.
Eur J Clin Invest. 2026 Jan;56(1):e70167. doi: 10.1111/eci.70167. Epub 2026 Jan 3.